Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- GYRE
- Price
- 8.07
- Stock movement down
- -0.18 (-2.33%)
- Company name
- Gyre Therapeutics Inc.
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Markedsverdi
- 685.74M
- Ent verdi
- -
- Pris/omsetning
- -
- Pris/bok
- -
- Utbytte avkastning
- -
- Utbytte vekst
- -
- Vekst år
- -
- FCF-utbetaling
- -
- Etterfølgende P/E
- -
- Fremtidig P/E
- 27.45
- PEG
- -
- EPS-vekst
- -
- 1 års avkastning
- -35.80%
- 3 års avkastning
- -35.66%
- 5 års avkastning
- -37.60%
- 10 års avkastning
- -46.36%
Sist oppdatert: 2025-09-12
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UTBYTTE
GYRE betaler ikke utbytte
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VERDSETTELSE
Verdsettelsesforhold
Loading...
Verdsettelsesforhold-data
| Etterfølgende P/E | - |
| Pris til OCF | - |
| Pris til FCF | - |
| Pris til EBITDA | - |
| EV i forhold til EBITDA | - |
Verdsettelse (Salg/Bokført verdi)
Loading...
Verdsettelse (Salg/Bokført verdi) data
| Pris til omsetning | - |
| Pris til bok | - |
| EV i forhold til salg | - |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
ØKONOMI
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
AKSJEINFORMASJON
Aksjediagram
Loading...
Aksjekurs-data
| Åpning | 7.75 |
| Daglig høy | 7.75 |
| Daglig lav | 7.47 |
| Daglig volum | 42K |
| Tidenes høyeste | 47155.50 |
| 1 år analytikerestimat | 19.00 |
| Beta | - |
| EPS (TTM) | - |
| Utbytte per aksje | - |
| Ex-div dato | 13 Jan 2023 |
| Neste dato for resultatpresentasjon | 12 Nov 2025 |
Nedsidepotensial
Loading...
Nedsidepotensial-data
| GYRE | S&P500 | |
| Nåværende prisfall fra toppnotering | -99.98% | -1.46% |
| Høyeste prisfall | -99.99% | -56.47% |
| Dato for høyeste fall | 28 Mar 2023 | 9 Mar 2009 |
| Gj.snittlig fall fra topp | -75.35% | -10.99% |
| Gj.snittlig tid til ny topp | 84 days | 12 days |
| Maks tid til ny topp | 3640 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
SELSKAPSOPPLYSNINGER
Markedsverdi
685.74M
Markedsverdi kategori
Small-cap
Beskrivelse
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY, under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573 is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
Ansatte
579
Nettsted
Investorrelasjoner
-
SEC-innsendelser
Adm. direktør
Land
USA
By
Aksjetype
-
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRESENTASJONER
ArrangementerPresentasjoner
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FORSTÅ VIRKSOMHETEN
Loading...
NYHETER OM SELSKAPET
Seeking AlphaPressemeldinger
iO Charts is a Seeking Alpha partner